Skip to main content

Table 1 Clinicopathological demographics of patients treated surgically for RCC with vena caval tumour thrombus

From: Impact of sarcomatoid differentiation and rhabdoid differentiation on prognosis for renal cell carcinoma with vena caval tumour thrombus treated surgically

Characteristics

Pure RCC (n = 97)

RCC with sarcomatoid and/or rhabdoid differentiation (n = 28)

p

Age (years), median (IQR)

60 (53–67)

55 (52–63)

0.205

Gender, n (%)

  

0.614

 Male

68 (70.1)

21 (75.0)

 Female

29 (29.9)

7 (25.0)

Tumour side, n (%)

  

0.510

 Left

25 (25.8)

9 (32.1)

 Right

72 (74.2)

19 (67.9)

Tumour size (cm), mean ± SD

8.5 ± 3.2

10.4 ± 4.1

0.012

Thrombus level (Mayo), n (%)

  

0.790

0.038

0.319

 I

29 (29.9)

9 (32.1)

 II

40 (41.2)

9 (32.1)

 III

19 (19.6)

6 (21.4)

 IV

9 (9.3)

4 (14.3)

Blood transfusion (cc), median (IQR)

400 (0–2000)

1600 (400–3200)

Tumour stage, n (%)

  

 T3b

84 (86.6)

21 (75.0)

 T3c

9 (9.3)

4 (14.3)

 T4

4 (4.1)

3 (10.7)

Nodal status, n (%)

  

1.000

 N0/Nx

88 (90.7)

26 (92.9)

 N+

9 (9.3)

2 (7.1)

Metastatic status, n (%)

  

0.060

 M0

76 (78.4)

17 (60.7)

 M1

21 (21.6)

11 (39.3)

Metastatic sites, n (%)

  

0.701

 Lung

16 (64.0)

8 (57.1)

 Bone

6 (24.0)

5 (35.7)

 Liver

3 (12.0)

1 (7.1)

Histologic subtype, n (%)

  

0.454

 Clear cell RCC

77 (79.4)

24 (85.7)

 Non-clear cell RCC

20 (20.6)

4 (14.3)

Fuhrman grade, n (%) (n = 120)

  

0.018

 1–2

38 (40.4)

4 (15.4)

 3–4

56 (59.6)

22 (84.6)

Tumour necrosis, n (%)

  

0.015

 Absent

53 (54.6)

8 (28.6)

 Present

44 (45.4)

20 (71.4)

Adjuvant target therapy

38(39.2)

11(39.3)

0.992

  1. RCC renal cell carcinoma, IQR interquartile range, SD standard deviation